The global preclinical imaging market size was estimated to be US$ 3.3 billion in 2021 and is expected to grow at a CAGR of 3% between 2023 to 2032.
Imaging is one of the most important methods of research that is employed by scientists. Observations to identify minute changes in physiological or environmental parameters require powerful detection and imaging tools. Research in animal models employing non-invasive, in vivo imaging modalities is predominant in the current age. Preclinical imaging, therefore, means the visualization of tissue, cells, or biochemical interactions within a living organism for research purposes.
Preclinical techniques enable a reduction in invasive methods, biological variability, and the number of animals or samples that are required to generate good results. Understanding the spatiotemporal distribution of physiological processes, precise in vivo characterization, live tracking, and diagnosis are achieved with relative ease owing to the development of advanced preclinical imaging tools. Drug delivery systems and efficacy studies are also successfully done by the use of several preclinical imaging apparatuses
Large pharmaceutical companies are increasingly utilizing small-animal imaging techniques to understand the complications and significance of their products before clinical trials. Outsourcing of research to the increasing number of clinical research organizations (CRO) is enabling the preclinical imaging market. This combined with overall growth in pharmaceutical research output is helping sales of preclinical imaging devices and tools.
The growth of the global preclinical imaging market is therefore primarily driven by increased investment/ funding by corporations and governments, along with constant technological developments in the research imaging sector. Changing outlook of researchers for traditional methods and the rising demand for non-invasive techniques are also observed to be driving the growth of the preclinical imaging market.
Furthermore, veterinary hospitals and educational/academic institutes are providing small yet significant contributions to the growth of this sector. The global preclinical market report generated through extensive research will help you better understand the market conditions for the next decade.
The increased restriction and enforcement of regulations placed on animal testing are impeding the adoption of preclinical imaging tools to a certain extent. Alternative testing techniques such as in vitro experimentations, micro-dosing studies, bioinformatics-based approaches, and virtual drug testing are limiting the sales prospects for preclinical imaging markets. However, non-invasive imaging techniques like MRI and CT scans are enabling positive growth.
The Covid-19 pandemic also had a considerable dampening effect on the growth of the preclinical imaging market. The negative effects can be attributed to delayed production, delivery, and shortages of reagents caused by lockdown measures. However, the preclinical imaging market is returning to normalcy quicker. You can get detailed statistics on the Covid-19 related disruption in our global preclinical imaging market report.
The constant pace of advancement in newer methods and tools is widening the application and usability of preclinical imaging tools. Oncology research has become one of the largest segments for use of preclinical imaging tools. The development of devices with higher sensitivity, the use of digital technologies, along with simpler UI will enable the preclinical imaging market to make a significant impact in cardiology, obstetrics, and gynaecology research.
New techniques such as micro-CT and micro-MRI combined with functional experimentation such as micro-Positron Emission Tomography (PET) are broadening the horizon in various domains of research. This in turn is increasing the adoption of various preclinical imaging tools by researchers.
The preclinical imaging market is currently dominated by optical imaging tools and products owing to their widespread use in small-animal imaging and drug development. Optical imaging tools are therefore garnering the highest revenue in this sector. This segment is expected to keep its lead intact during the study period.
However, multimodal imaging devices will see higher growth rates as the technology advances further. The development of integrated digital imaging systems that may have multiple screenings are better suited for molecular and anatomical studies and is expected to break even. The generation of such tools and devices will boost new product catalogues and the overall interest of researchers in the preclinical imaging market.
Apart from devices, the reagent segment accounts for a significant share of revenue in the preclinical imaging market. The higher ratio of sales and revenue is because of the frequent use of reagents and their routine replenishments. Fluorescent and bioluminescent reagents, preclinical nuclear imaging chemicals, and preclinical PET tracers are some of the biggest types of reagents with high sales and revenue. The rise in the purchase of new devices will also spur growth in the preclinical imaging reagent market as well.
The North American market is the leader in terms of sales and revenue growth observed for the global preclinical imaging market. A large number of preclinical research projects, high-quality research infrastructure, and availability of skilled human resources are driving the adoption and rise of preclinical research methods and tools across this region. Similarly, government funding and initiatives are encouraging more clinical R&D projects, especially in the United States and Canada. The tax credit is another factor contributing to research in the preclinical domain. Due to these factors, North America is expected to maintain its lead and grow the preclinical imaging market significantly.
The Asia Pacific region is also looking at a possibly high growth rate for the preclinical imaging market. Low cost of research and manpower, less stringent regulations, rising talent pool are the factors that will increase preclinical R&D initiatives. As a result, clinical research outsourcing is a booming industry in India and China. This growing industry will also enable the rise of the preclinical imaging market both regionally and globally.
Initiatives such as acquisitions, product upgrades, portfolio diversification, and regional expansion are happening in the preclinical imaging markets across the world. Additional initiatives like academic collaborations and outsourcing are creating new opportunities in preclinical imaging markets. The rise of investment and increased funding is bringing new players which in turn may help the preclinical imaging market expand rapidly.
The major players operating in the preclinical imaging market are Agilent Technologies, Bruker Corporation, Mediso Ltd., MILabs B.V., MR Solutions, Molecubes Inc., General Electric (GE), PerkinElmer, Inc., Siemens A.G., TriFoil Imaging, VisualSonics Inc. (Fujifilm) are leading the market of preclinical imaging products and technology.
By End User
Preclinical research tools are useful in diagnosing, detecting, and researching physiological functions in small-animal models without any invasive methods.
The Global Preclinical Imaging Market was negatively impacted due to the Covid-19 pandemic. Nevertheless, the sector is expected to normalize and ensure enhanced growth within the next decade.
The global preclinical imaging market size was estimated to be US$ 3.3 billion in 2021.
The global preclinical imaging market is estimated to exhibit a CAGR of 3% between 2023 to 2032.
The growth of the global preclinical imaging market is therefore primarily driven by increased investment/ funding by corporations and governments, along with constant technological developments in the research imaging sector. Changing outlook of researchers for traditional methods are observed to be driving the growth of the preclinical imaging market.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved